Given that loss-of-function in TET2 is known to confer a poor prognosis in AML (Kosmider et al., 2009; Chou et al., 2011), vitamin C deficiency could fuel increased disease aggressiveness or risk of relapse even in non-TET mutant cancer patients. The gene discussed is TET2; the disease is acute myeloid leukemia.